CVALF
Price
$1.53
Change
-$0.07 (-4.38%)
Updated
Sep 26 closing price
Capitalization
42.02M
MBIO
Price
$1.55
Change
-$0.04 (-2.52%)
Updated
Sep 29, 04:59 PM (EDT)
Capitalization
11.51M
Interact to see
Advertisement

CVALF vs MBIO

Header iconCVALF vs MBIO Comparison
Open Charts CVALF vs MBIOBanner chart's image
Covalon Technologies
Price$1.53
Change-$0.07 (-4.38%)
Volume$2.2K
Capitalization42.02M
Mustang Bio
Price$1.55
Change-$0.04 (-2.52%)
Volume$693
Capitalization11.51M
CVALF vs MBIO Comparison Chart in %
Loading...
CVALF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CVALF vs. MBIO commentary
Sep 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CVALF is a Hold and MBIO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 29, 2025
Stock price -- (CVALF: $1.53 vs. MBIO: $1.59)
Brand notoriety: CVALF and MBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CVALF: 31% vs. MBIO: 30%
Market capitalization -- CVALF: $42.02M vs. MBIO: $11.51M
CVALF [@Biotechnology] is valued at $42.02M. MBIO’s [@Biotechnology] market capitalization is $11.51M. The market cap for tickers in the [@Biotechnology] industry ranges from $98.9B to $0. The average market capitalization across the [@Biotechnology] industry is $1.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CVALF’s FA Score shows that 0 FA rating(s) are green whileMBIO’s FA Score has 0 green FA rating(s).

  • CVALF’s FA Score: 0 green, 5 red.
  • MBIO’s FA Score: 0 green, 5 red.
According to our system of comparison, MBIO is a better buy in the long-term than CVALF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CVALF’s TA Score shows that 3 TA indicator(s) are bullish while MBIO’s TA Score has 5 bullish TA indicator(s).

  • CVALF’s TA Score: 3 bullish, 6 bearish.
  • MBIO’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, MBIO is a better buy in the short-term than CVALF.

Price Growth

CVALF (@Biotechnology) experienced а -5.20% price change this week, while MBIO (@Biotechnology) price change was -4.79% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.00%. For the same industry, the average monthly price growth was +11.11%, and the average quarterly price growth was +59.53%.

Industries' Descriptions

@Biotechnology (+2.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CVALF($42M) has a higher market cap than MBIO($11.5M). CVALF has higher P/E ratio than MBIO: CVALF (23.63) vs MBIO (0.80). CVALF YTD gains are higher at: -31.696 vs. MBIO (-82.034). CVALF has higher annual earnings (EBITDA): 3.14M vs. MBIO (-5.6M). CVALF has more cash in the bank: 18.1M vs. MBIO (12.7M). MBIO has less debt than CVALF: MBIO (0) vs CVALF (1.28M). CVALF has higher revenues than MBIO: CVALF (33M) vs MBIO (0).
CVALFMBIOCVALF / MBIO
Capitalization42M11.5M365%
EBITDA3.14M-5.6M-56%
Gain YTD-31.696-82.03439%
P/E Ratio23.630.802,957%
Revenue33M0-
Total Cash18.1M12.7M143%
Total Debt1.28M0-
FUNDAMENTALS RATINGS
CVALF vs MBIO: Fundamental Ratings
CVALF
MBIO
OUTLOOK RATING
1..100
5032
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
90
Overvalued
PROFIT vs RISK RATING
1..100
72100
SMR RATING
1..100
74100
PRICE GROWTH RATING
1..100
8549
P/E GROWTH RATING
1..100
7558
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CVALF's Valuation (61) in the null industry is in the same range as MBIO (90) in the Pharmaceuticals Major industry. This means that CVALF’s stock grew similarly to MBIO’s over the last 12 months.

CVALF's Profit vs Risk Rating (72) in the null industry is in the same range as MBIO (100) in the Pharmaceuticals Major industry. This means that CVALF’s stock grew similarly to MBIO’s over the last 12 months.

CVALF's SMR Rating (74) in the null industry is in the same range as MBIO (100) in the Pharmaceuticals Major industry. This means that CVALF’s stock grew similarly to MBIO’s over the last 12 months.

MBIO's Price Growth Rating (49) in the Pharmaceuticals Major industry is somewhat better than the same rating for CVALF (85) in the null industry. This means that MBIO’s stock grew somewhat faster than CVALF’s over the last 12 months.

MBIO's P/E Growth Rating (58) in the Pharmaceuticals Major industry is in the same range as CVALF (75) in the null industry. This means that MBIO’s stock grew similarly to CVALF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CVALFMBIO
RSI
ODDS (%)
Bullish Trend 4 days ago
75%
Bullish Trend 4 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
60%
Bearish Trend 4 days ago
90%
Momentum
ODDS (%)
Bearish Trend 6 days ago
68%
Bullish Trend 4 days ago
81%
MACD
ODDS (%)
Bearish Trend 4 days ago
75%
Bullish Trend 4 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
63%
Bearish Trend 4 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
62%
Bullish Trend 4 days ago
73%
Advances
ODDS (%)
N/A
Bullish Trend 11 days ago
81%
Declines
ODDS (%)
Bearish Trend 26 days ago
69%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
87%
Bullish Trend 4 days ago
70%
Aroon
ODDS (%)
Bearish Trend 4 days ago
72%
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CVALF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TORXF41.161.13
+2.82%
Torex Gold Resources Inc.
PVARF10.00N/A
N/A
Porvair PLC
SQCF15.62N/A
N/A
Susquehanna Community Financial, Inc.
RREE0.20N/A
N/A
ResourceTec Corporation
ETTYF26.02N/A
N/A
Essity Aktiebolag Publ

CVALF and

Correlation & Price change

A.I.dvisor tells us that CVALF and SMMT have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CVALF and SMMT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CVALF
1D Price
Change %
CVALF100%
-4.38%
SMMT - CVALF
27%
Poorly correlated
+3.41%
GNFT - CVALF
25%
Poorly correlated
+0.45%
AKBLF - CVALF
21%
Poorly correlated
N/A
TARA - CVALF
21%
Poorly correlated
-0.93%
MBIO - CVALF
20%
Poorly correlated
-0.62%
More

MBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, MBIO has been closely correlated with SLRX. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if MBIO jumps, then SLRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MBIO
1D Price
Change %
MBIO100%
-0.62%
SLRX - MBIO
71%
Closely correlated
-3.54%
MDGL - MBIO
50%
Loosely correlated
+0.29%
ORMP - MBIO
44%
Loosely correlated
+0.42%
AXON - MBIO
40%
Loosely correlated
-0.46%
SCNI - MBIO
38%
Loosely correlated
-1.49%
More